Observational findings associate lower adverse events with lipid-lowering medications in patients with high plaque burden, indicating potential prevention strategies.
In symptomatic patients with suspected CAD, LLM after coronary computed tomography angiography was associated with a lower rate of adverse events during long-term follow-up among those with PAV >5%, even in the absence of obstructive CAD. The quantification of coronary atherosclerotic plaque burden is a potential marker to guide preventive lipid-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Maaniitty et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: